Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors

Major Program

Supportive Care and Symptom Management

NCI Community Oncology Research Program

Research Group

Community Oncology and Prevention Trials

Status

Recruiting

NCT ID

NCT04871542

This study examines how certain risk factors (such as age, gender, other medical conditions, and the type of immunotherapy used to treat the cancer) affect whether a patient with a malignant solid tumor will develop mild or serious side effects from the immunotherapy medications. Immunotherapy is the type of treatment that helps the body's immune system fight cancer. In the future, this information may help doctors make better decisions about cancer treatments.

Intervention

Biospecimen Collection, Questionnaire Administration

Condition

Malignant Solid Neoplasm

Investigators

Krishna S Gunturu, Debra M. Prow, Site Public Contact

CT Research Area

Symptom Science

See list of participating sites